|
What is our research strategy?
Our strategy is to be able to invest into paediatric oncology, so that a
cure for children's cancer can be found. To do this, the training
facilities in Canada for health care professionals must be expanded.
While the proposal provides a mechanism to fund promising research that
may not otherwise be supported, the focus is to provide financial support
to build strong research teams, which will then be able to attract
research from other funding. These items will essentially increase the
field of paediatric oncology, and the various support systems that go
along with it.
Partnerships
A new partnership between Candlelighters Canada and the Canadian
Institute of Health Research was formalized in 2000. This will bring much
needed research dollars into the broad field of childhood cancer research
identifying causes, treatments, prevention and quality of life issues.
Cancer research is
the foundation to successful treatment, and Canada is home to a team of
internationally respected medical experts in the field of childhood
cancer research and treatment. Candlelighters Canada supports the
application of science, technology and medicine in the prevention,
treatment, care and control of cancer in children. Research improves the
clinical care of cancer patients. Candlelighters's goal is to help
improve the quality of life for children with cancer and their families,
and better understand the processes that lead to the development and cure
of childhood cancer.
Fellowship
Candlelighters Canada
has formed a partnership with the Canadian Institutes of Health Research
(CIHR) to fund childhood cancer fellowships. This entails research into a
specific field of study pertaining to the search for the cure for
childhood cancer.
There are currently
three people partaking in this fellowship program. The fields of study are:
(a)
Development
of Novel Strategies to Enhance Anti-Leukemia Immune responses.
(b)
Human
Model System for Congenital Fibromyosarcoma.
(c)
Tumour
Genesis Mechanisms of Childhood Eye Cancer, Retinoblastoma and the
Effects of Low Penetrance Mutations
|
